Tirzepatide Discontinuation and Reinitiation for Diabetes

(CLIN-GLP1 Trial)

This trial explores how stopping and restarting tirzepatide, a medication that controls blood sugar and appetite, affects brain activity, mood, hunger, and daily life in current users. Researchers will assess participants' brain responses to food and overall well-being at different stages: while on the medication, during a short break, and after restarting. The study seeks individuals currently using tirzepatide and receiving care from the University of Texas-Southwestern Weight Wellness Clinic. As an unphased trial, it offers participants the chance to contribute to a deeper understanding of tirzepatide's effects on brain activity and overall well-being.

The trial specifically involves stopping and restarting tirzepatide, so you will need to pause this medication for 3-4 weeks as part of the study. The protocol does not mention other medications, but it requires that you are not using any other weight-affecting medications.

Research shows that tirzepatide is generally well-tolerated by adults with type 2 diabetes and obesity. Many people experience common side effects like nausea, vomiting, diarrhea, and reduced appetite. These side effects are usually mild and tend to resolve over time. However, rare cases of more serious issues, such as gallbladder problems, have occurred.

Researchers are excited about tirzepatide for diabetes because it offers a unique approach compared to existing treatments. Unlike most diabetes medications that typically target a single hormone, tirzepatide is a dual-action drug, meaning it mimics both GLP-1 and GIP hormones, which play crucial roles in blood sugar regulation. This dual action could potentially lead to more effective blood sugar control and weight loss than current treatments. Additionally, tirzepatide's ability to work on multiple pathways may translate to improved outcomes for patients who haven't found success with other medications.

Research has shown that tirzepatide, the investigational treatment in this trial, effectively manages type 2 diabetes. Studies indicate that tirzepatide significantly lowers blood sugar levels and aids in weight loss. For instance, one study found that patients taking tirzepatide experienced a 1.1% greater drop in their A1c levels (a measure of blood sugar) compared to another diabetes medication. Additionally, people using tirzepatide lost an average of 7.2 kilograms (about 16 pounds) over 40 weeks. Another study found that some participants lost up to 15.7% of their body weight after 72 weeks. These findings suggest that tirzepatide is a strong option for managing diabetes and related health issues.⁶⁷⁸⁹¹⁰